Executive Summary

• The National Vaccine Injury Compensation Program (VICP) is a long-standing federal program designed to preserve vaccine supply and demand, stabilize costs, and prevent liability spirals while compensating individuals who experience rare injury from covered vaccines.
• Over time, the VICP has garnered attention beyond its narrow compensation mechanism; administrative delays, debates over compensation standards, and broader political disputes over vaccine policy have all intensified questions about the program.
• Proposals intended to weaken the VICP rather than reform or strengthen it risk jeopardizing efficient relief for the injured, further eroding vaccine development, curtailing vaccine availability, and limiting the enormous public health benefits from broad-based immunization.

Introduction

The National Vaccine Injury Compensation Program (VICP) is a foundational but often underappreciated component of the United States’ vaccine policy framework. In response to mounting liability pressures that threatened vaccine supply and market stability in the 1980s, Congress created the VICP as a no-fault compensation system intended both to provide appropriate redress for vaccine-related injuries and to preserve the legal and economic conditions necessary for continued vaccine development and distribution.

Over time, the VICP has garnered attention beyond its narrow compensation mechanism. It sits at the intersection of tort law, federal health policy, scientific adjudication, and industrial strategy, serving as a stabilizing institution for both vaccine manufacturers and the broader immunization system. Its operations reflect the delicate balance that policymakers sought to strike: ensuring that individuals with legitimate claims have access to fair and timely compensation while protecting a socially and medically indispensable industry from the volatility of conventional litigation. That balance has been critical not only to the continuity of vaccine supply, but also to the public health infrastructure that depends upon the relative predictability of routine immunization.

Today, however, the VICP faces renewed scrutiny. Administrative delays, debates over compensation standards, the necessary separation between the VICP and the Countermeasures Injury Compensation Program (CICP) during the COVID-19 era, and broader political disputes over vaccine policy all have intensified questions about whether and how the program should change. Those debates carry significance far beyond the claims process itself. Any substantial alteration to the VICP could affect the program’s ability to provide efficient restitution to injured persons, manufacturer incentives, public confidence in vaccine governance, and the long-term resilience of the nation’s immunization system. Accordingly, understanding the VICP requires more than a review of its legal design; it requires recognizing the program as a central part of the system that has long undergirded U.S. vaccination policy.

Background

The VICP plays an unusual but essential role in the architecture of American public health. Created by the National Childhood Vaccine Injury Act of 1986 and operational since 1988, the program was designed as a no-fault alternative to ordinary vaccine litigation. Its purpose was not simply to compensate any individual with a legitimate claim of injury by a covered vaccine. It was also meant to preserve vaccine supply and demand, stabilize costs, and prevent the kind of liability spiral that could drive manufacturers from a market that public health depends upon.

The VICP’s genesis lies in the vaccine-liability crisis of the early 1980s, especially surrounding diphtheria-tetanus-pertussis (DTP) vaccines. As lawsuits increased after allegations linking DTP to severe neurological injury, manufacturers faced rising legal exposure. Some exited the market and prices for the remaining products rose sharply. Policymakers grew concerned that continued instability could reduce vaccination rates and invite the return of vaccine-preventable disease. Congress responded by creating a specialized compensation system that would channel most claims away from the traditional tort system and into a federally administered process. The basic premise was straightforward: People alleging vaccine injury would have access to compensation without having to prove wrongdoing. Meanwhile, manufacturers and administrators would be protected from direct tort liability in most cases, but subject to a separate, product-specific legal liability regime.

That legislative design still defines the program today. A person alleging injury from a covered vaccine files a petition in the U.S. Court of Federal Claims, where cases are handled by the Office of Special Masters, a dedicated set of judges with specific expertise and history in these cases. The program uses a vaccine injury table that lists covered vaccines, injuries, and timeframes. If a petitioner shows that a listed injury occurred within the specified period, causation is presumed unless another cause is shown. If the claim falls outside the table, the petitioner can still pursue legal remedies through civil litigation but are held to a different evidentiary standard and must prove causation. This structure is important because it lowers evidentiary barriers in some cases while still preserving a scientific and legal framework for evaluating more complex claims. The program is funded through a federal excise tax of $0.75 per disease prevented by a covered dose, meaning, for example, that a bivalent vaccine and a trivalent vaccine are not taxed equally.

The Current Vaccine Injury Table

A central feature of the VICP is the Vaccine Injury Table, codified at 42 C.F.R. § 100.3 and currently effective for claims filed on or after January 3, 2022. The table identifies covered vaccines, specific injuries or conditions associated with those vaccines, and the time period in which the first symptom or manifestation of onset must occur. If a petitioner demonstrates that a listed injury followed a covered vaccine within the specified time window and satisfies the table’s definitional requirements, causation is presumed unless another cause is shown. If the alleged injury is not listed, or if it falls outside the table’s timing or definitional requirements, the petitioner may still seek compensation but must prove causation through evidence such as medical records and expert testimony through the traditional civil litigation system. The table therefore serves both as a gateway to a rebuttable presumption of causation and as a way of structuring the distinction between “table” and “off-table” claims.

The current table is organized by vaccine category and includes a defined set of injuries rather than an open-ended list of all possible adverse events. Some listed injuries are specific to certain vaccines, while others appear across many categories. For example, the table includes recurring entries such as anaphylaxis, shoulder injury related to vaccine administration, and vasovagal syncope for a number of covered vaccines. It also identifies more vaccine-specific injuries for certain products, such as chronic arthritis following rubella-containing vaccines, intussusception after rotavirus vaccines, and Guillain-Barré syndrome after seasonal influenza vaccines. In addition, the regulation makes clear that the table covers not only the listed injury itself, but also acute complications or sequelae that may follow from it, including death in appropriate cases. In practice, the Vaccine Injury Table is one of the VICP’s most important structural features because it translates the program’s broad statutory promise of compensation into a more concrete framework for evaluating claims.

Historical Perspective

The VICP’s historical operations show both its scale and its caution. According to a Health Resources and Services Administration’s (HRSA) January 2026 report, more than 29,000 petitions have been filed since 1988, 25,652 have been adjudicated, 12,588 have been compensated, and total compensation paid has reached roughly $5.5 billion. For covered vaccines distributed from 2006 through 2023, HRSA reports that more than 5 billion doses were distributed and approximately one individual was compensated for every 1 million doses distributed. This statistic underscores two realities at the same time: Serious vaccine injuries are rare, but the compensation system is not merely symbolic. It exists because rare harms do occur, and because a successful immunization system must be able to acknowledge that fact without collapsing into indiscriminate litigation.

The program also clarifies a point often lost in public debate: Compensation is not the same thing as definitive scientific proof that a vaccine caused an injury in every paid case. HRSA notes that approximately 60 percent of compensation awarded by the VICP comes through negotiated settlements in which the Department of Health and Human Services (HHS) has not concluded, based on its review of the evidence, that the vaccine caused the alleged injury. Settlements can reflect litigation risk, cost, time, and administrative efficiency rather than a formal merits determination. This does not make the system illegitimate; to the contrary, it reflects the hybrid character Congress created. The VICP is meant to be more accessible and less adversarial than ordinary litigation, while still grounded in rules of evidence, medical review, and judicial oversight. Later amendments, including the 21st Century Cures Act, expanded that framework to include certain vaccines routinely recommended during pregnancy and claims involving live-born children injured in utero, showing that the program has evolved with changes in vaccination practice.

Institutional Roles in the VICP

The VICP is often described as a single federal program, but in practice it is a statutory and institutional framework involving Congress, multiple executive-branch agencies, and the U.S. Court of Federal Claims, with distinct roles in determining which vaccines are covered, how claims are administered, how cases are litigated, and who ultimately decides whether compensation is awarded. It is best understood in sequence. Congress established the legal structure for VICP and entrusted the maintenance of its trust fund to the Treasury. The Food and Drug Administration (FDA) regulates the approval of a vaccine, and if approved, the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) shape whether that vaccine enters the routine immunization framework. If the vaccine does, the HHS secretary formally brings eligible vaccines into the program, after which HRSA administers the review and payment systems. The Department of Justice (DOJ) represents the government in litigation while the Office of Special Masters adjudicates claims.

This division of labor is part of what makes the VICP’s unique structure more stable and less subject to political capriciousness. It is neither purely a health-agency program nor simply a court-based compensation fund. Instead, it works broadly within public health policy, administrative governance, scientific review, and federal adjudication.

As noted above, Congress created the VICP through statute and – though not operationally involved on a day-to-day basis – remains central to program stability and maintenance via the excise tax levied on each eligible vaccine. Congress must approve that tax before a vaccine can become VICP-covered. In other words, Congress is not simply part of the program’s backstory; it defines the legal structure within which the rest of the institutions operate.

The key starting point of the VICP coverage cycle is the FDA. The agency does not adjudicate VICP petitions or award compensation, but it licenses vaccines, regulates manufacturer obligations, and helps oversee post-market safety reporting. Together with CDC, the FDA participates in the Vaccine Adverse Event Reporting System, which helps shape the broader safety and evidentiary environment surrounding vaccines. FDA’s role in the VICP is therefore indirect but significant: It governs the product and the regulatory record around it, even though it does not decide whether any individual petitioner should recover.

After licensure, CDC and ACIP help determine whether a vaccine moves into the routine immunization framework that matters for VICP coverage. ACIP advises the CDC director on vaccine use, and once those recommendations are adopted, they become official federal guidelines. That matters because, under HRSA’s description of the program, a vaccine generally must be recommended for routine administration to children or pregnant women before it can be brought within the VICP. ACIP therefore does not resolve claims, but it has substantial upstream influence over which vaccines may enter the program at all.

The HHS secretary and HRSA then occupy the central executive-branch role in translating that policy framework into an operating compensation program. HRSA administers the VICP, manages program operations, supports review of petitions, and serves as the program’s administrative home within HHS. But the secretary also has an important gatekeeping function: once the relevant recommendation and tax requirements are met, the secretary must add the vaccine by regulation for it to become VICP-covered. That means HHS is not merely administering claims after the fact; it also helps determine the formal boundaries of the program itself.

The HHS secretary also works with the Advisory Commission on Childhood Vaccines (ACCV), which plays a separate advisory role focused specifically on the VICP itself. Unlike ACIP, which addresses vaccine-use recommendations, the ACCV advises the secretary of HHS on issues related to the operation and improvement of the compensation program. It does not adjudicate claims, but it serves as a built-in mechanism for oversight and policy feedback.

Once a petition is filed, the process becomes more explicitly legal. DOJ’s Office of Vaccine Litigation represents HHS in the U.S. Court of Federal Claims and presents the government’s position in individual cases. The actual adjudicator, however, is the Court of Federal Claims through its congressionally created Office of Special Masters, which manages vaccine cases and determines whether a petitioner is entitled to compensation. That division is worth emphasizing because it captures the VICP’s hybrid design: Executive agencies administer and defend the program, but entitlement is ultimately decided in a judicial forum rather than by HHS alone.

Taken together, these roles show that the VICP depends on more than one agency’s judgment. CDC and ACIP influence which vaccines may enter the program, HHS and HRSA administer it, FDA shapes the regulatory and safety context, DOJ litigates the government’s position, the Court of Federal Claims adjudicates entitlement, Treasury and the Internal Revenue Service sustain the trust fund, and the ACCV advises on the program’s ongoing operation. Understanding that institutional structure is important because any serious reform to the VICP is likely to affect not just one agency, but the broader vaccine-policy framework the program was designed to support.

Current Controversies

Historically, debate over the VICP was often centered on administrative fairness or legal design. In recent months, however, the VICP has been drawn more directly into broader conflicts over vaccine policy, scientific advisory structures, and the direction of federal health governance. Public reporting has documented several proposed overhauls to the program, including efforts to remove and replace members of federal advisory bodies connected to vaccine policy and compensation due to perceived industry capture. The result is that debate over the VICP now extends beyond questions of administrative fairness or legal design. It has become part of a larger struggle over whether vaccine policy will continue to be shaped primarily through established scientific and institutional processes or through a more ideological and openly political framework.

Related to that politicization is a more specific controversy over the Vaccine Injury Table itself. A recent petition urged HHS to expand the table dramatically, from the current list of recognized injuries to more than 300 conditions, and threatened litigation if the department declined to act. That dispute matters because the table is not merely descriptive; it helps determine when claimants benefit from a presumption of causation rather than having to prove causation case by case. Expanding it substantially would therefore change more than the program’s wording. It could alter the evidentiary balance at the core of the VICP and raise a deeper question about whether the program should remain anchored to a relatively disciplined scientific standard or be broadened in ways that make compensation easier to obtain but less tethered to established causal evidence.

Concerns also abound regarding the program’s dependence on the broader federal recommendation framework. A vaccine category must generally be recommended for routine administration, be subject to a federal excise tax, and be added by the HHS secretary before it becomes covered by the program. That structure means changes to vaccine recommendations do not remain confined to clinical guidance; they can also affect the scope and predictability of the compensation system itself. Recent legal disputes over changes to childhood vaccine recommendations have made that vulnerability more visible. Even apart from the outcome of those cases, they illustrate that when the recommendation process becomes unstable or politically contested, the legal framework supporting VICP coverage can become less certain as well.

Current controversies surrounding the VICP cannot be dismissed as anti-vaccine rhetoric alone, however. Defenders of the program acknowledge that it needs modernization. The program remains a functioning alternative to ordinary tort litigation, but some argue that it has not been modernized sufficiently to remain as efficient and accessible as Congress intended. HRSA’s March 2026 report states that it takes, on average, two to three years to adjudicate a petition, while the Court of Federal Claims notes that all vaccine claims are handled by an Office of Special Masters consisting of only eight special masters. At the same time, the program’s compensation structure still reflects older statutory assumptions: Pain-and-suffering awards and death benefits remain capped at $250,000, a limit some commentators and reform advocates argue no longer reflects inflation or the severity of certain injuries. Taken together, those features have made modernization a serious point of contention, with critics arguing that the program needs greater adjudicatory capacity, more up-to-date compensation rules, and administrative reforms that reflect today’s broader and more complex immunization landscape. Yet there is a meaningful distinction between reforming VICP to make it work better and reshaping it in ways that could undermine its original purpose.

Changes to VICP Alter the Future of Public Health

The importance of the VICP to the vaccine development industry is substantial. Vaccines are not ordinary consumer products. They are administered broadly, often to healthy people, because their principal value lies in preventing future illness at both the individual and community level. That creates a difficult liability profile: The products are socially indispensable, but the public is often less tolerant of even rare adverse events when the recipient was not already sick. By channeling claims into a specialized compensation system, the VICP reduces the risk that tort exposure will destabilize manufacturing incentives. The Supreme Court’s decision in Bruesewitz v. Wyeth reinforced that structure by recognizing that the statute affords manufacturers significant protection from certain design-defect claims after petitioners first proceed through the compensation system. The industry significance of VICP, then, is not abstract. It helps maintain a legal environment in which companies can remain in the vaccine market and invest in products that public health agencies rely upon.

What would changing the VICP mean for the future of public health? The answer depends almost entirely on the direction of change. Reform aimed at increasing adjudicatory capacity, improving transparency, updating compensation rules, and preserving scientific standards could strengthen confidence in the program and demonstrate that vaccine policy can acknowledge rare harms with scientific validity. But reform that expands compensation untethered from credible evidence weakens the liability bargain that has long supported vaccine supply and makes coverage contingent on unstable political judgments. Such contrived reform would inject uncertainty into one of the core legal structures supporting U.S. immunization policy. Because vaccines depend on public confidence, functioning supply chains, and manufacturer participation all at once, even small changes to this framework can have outsized downstream effects.

Conclusion

The VICP was created to manage a difficult truth: Vaccines are indispensable to public health, but no medical intervention is wholly risk free. For four decades, the program has attempted to reconcile that reality by providing restitution to people who experience rare injuries while providing some protection for the broader vaccine system from destabilizing litigation. Its record is imperfect, and administrative reform may well be warranted. But the central test of any future change should remain the same as it was in 1986: whether the program continues to provide fair redress without undermining vaccine development, vaccine availability, and the public-health benefits that broad immunization makes possible.